Dive into the fascinating world of Ozempic's scientific journey with Novo Nordisk's chief scientific advisor. Learn about the science behind weight loss on Ozempic, the 90s belief in a groundbreaking drug, and weight loss as a primary goal from the start. Explore the challenges and innovations in developing pharmaceutical technologies and the mechanisms of GOP one agents for diabetes and weight loss.

Meet Lotte Bjerre Knudsen, a young scientist at Novo Nordisk focusing on GLP-1 for diabetes treatment. Dive into the story of a breakthrough drug, Ozempic, and the race for a trillion-dollar market cap. Explore the impact of weight loss medications and the evolution of Simeglotide from diabetes treatment to weight loss solution.

Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk, is a trailblazer in GLP-1 drug development for obesity and Alzheimer's. She shares her journey from enzyme research to impactful innovations. The discussion dives into the surprising link between GLP-1 drugs and weight loss in Type 2 diabetes patients. Lotte also highlights the future of these treatments in tackling neurodegenerative diseases. Additionally, she addresses the challenges faced by women in science and the need for collaboration and equality in research.